AZ 13824374

Key Product Details

Product Description

AZ 13824374 is a potent and selective inhibitor of ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain (pIC₅₀ values are 6.2 and 8.2 in NanoBRET assay and FRET assay, respectively). It is >100-fold selective over a range of epigenetic targets from ROMOscan panel (DiscoveRx Corp.). AZ 13824374 shows cellular target engagement (cellular inhibition pIC₅₀ = 6.9) and antiproliferative activity in a range of breast cancer cell lines.

Licensing Information

Sold with the permission of AstraZeneca UK Ltd.

Product Specifications for AZ 13824374

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AZ 13824374

The following data is based on the product molecular weight 562.69.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.78 mL	8.89 mL	17.77 mL
5 mM	0.36 mL	1.78 mL	3.55 mL
10 mM	0.18 mL	0.89 mL	1.78 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Winter-Holt Discovery of a potent and selective ATAD2 bromodomain inhibitor with antiproliferative activity in breast cancer models. J.Med.Chem. 2022 PMID: 35133824

Product Documents for AZ 13824374